Awards Outside of ACOG

  • AMAG, through its subsidiary Lumara Health, has announced available 2016 Research Grants to address prematurity and improve neonatal health. Consideration will be given to basic or clinical research in maternal, fetal and neonatal/infant health.  All proposals will be evaluated and the final awards will be determined based on scientific merit by an external review panel comprised of experts in the field.   The panel will determine allocation of these funds, with no single recipient receiving more than $75,000 to allow for multiple grants to be provided.

    Interested researchers should complete an application and submit by August 15, 2016 to: jgudeman@amagpharma.comResearch awards are expected to be announced by October 31, 2016 with funds to be provided upon execution of a research grant contract, to ensure compliance with applicable regulations. 

    *The funds from this grant program should be used exclusively for the research program and are not to be designated as general overhead.

  • Nominate a researcher for the prestigious Eugene J. Van Scott Award for Innovative Therapy of the Skin and Phillip Frost Leadership Lecture. Offered by the American Academy of Dermatology and made possible through a generous contribution from Phillip Frost, MD, FAAD, this Award and Lecture is given in recognition of significant contributions toward an innovative therapy of the skin, hair and/or nails. Open to all; not restricted to a dermatologist.

  • OPERM provides grant funding, scientific expertise, a nonhuman primate (NHP) animal resource, laboratory and procedural infrastructure, and administrative support to investigators who wish to evaluate novel agents or procedures for permanent female contraception. The objective of OPERM is to identify and complete preclinical development of one or more approaches to nonsurgical permanent contraception in a nonhuman primate model such that the approach can be transitioned into early phase clinical trials in women.  A new method of nonsurgical female permanent contraception must be viewed as safe, voluntary, and non-coercive to become highly acceptable. To be successfully adopted, a new method of permanent female contraception will need to follow a careful path toward concurrent regulatory approval in both lesser- and more-developed nations. Since it is anticipated that approaches that adapt safe approved drugs or technologies from other fields may have fewer regulatory hurdles to overcome, these approaches are particularly welcomed. A list of currently-funded projects is available at on their website (

Specifically, we seek proposal that identify and test new lead agents suitable for transcervical delivery that will result in bilateral obstruction of the fallopian tubes without harmful non-target effects. Novel approaches to very long acting (at least 20 year) reversible methods will also be considered, but must offer substantial advantages to currently available methods such as copper intrauterine devices. All proposals should align with the target product profile of a new female permanent contraception method; low cost, portability, applicability for use in low resource settings by non-physicians, single treatment, and lack of interference with normal menstrual cycles. Proposals for immunocontraception and products that would require laparoscopy or hysteroscopy will not be considered.  

Applicants are required to submit a complete research proposal no later than October 31, 2016. Projects will be funded by January 1, 2017.

Grant application:  The electronic portal

Please contact Keri Brown ( for any questions

  • The NVA is seeking research proposals that will shed light on the underlying pathophysiological mechanisms that cause or maintain vulvodynia and treatment studies that include women over 45.  

If you are interested in applying, please send an email to Phyllis Mate ( by Monday, September 19, 2016 that includes a brief (1-2 paragraph) summary of your proposed study's design and objectives. Once we have received this information from you, we will email you a full application to complete and submit by Monday, October 31, 2016.

The maximum grant amount is between $25,000 and $30,000 and we require confirmation that all funds will be applied to direct research costs, not institutional costs. If you've previously applied and/or received grant support from the NVA, you are still eligible to apply. Summaries of studies that NVA has funded to date can be viewed on NVA's web site.

We welcome correspondence about potential projects. To discuss your proposal, please contact Phyllis Mate via email (

We try to carefully choose web sites, which we believe are useful and meet our high standards for the accuracy and utility of information. However, because web site design and content can change so quickly, we cannot guarantee the standards of every web site to which we link. Likewise, we are not responsible for the content of any non-ACOG site. We also cannot guarantee the privacy policies of these other sites and suggest you check the privacy policies of those sites directly. Should questions arise, please contact the granting organization directly.

American Congress of Obstetricians and Gynecologists
409 12th Street SW, Washington, DC  20024-2188 | Mailing Address: PO Box 70620, Washington, DC 20024-9998